Form 4: Quince Therapeutics CEO and CMO Boosts Stake with Significant Share and Warrant Acquisition

Sentiment:

Insider Transaction Report 23 June 2025 8:43 AM

📋All filings for Quince Therapeutics, INC

Quince Therapeutics' CEO and CMO, Dirk Thye, has significantly increased his direct beneficial ownership in the company by acquiring 150,944 common shares and an equal number of warrants.

Better than expectedThe CEO and CMO, Dirk Thye, significantly increased his stake in the company by acquiring common shares and warrants, which is typically viewed as a positive signal of management confidence and belief in the company's future prospects.

Summary

Dirk Thye, who serves as both CEO and CMO of Quince Therapeutics, Inc. (QNCX), reported changes in his beneficial ownership.
On June 18, 2025, Mr. Thye acquired 150,944 common shares of Quince Therapeutics at a price of $1.2 per share.
Following this transaction, his total direct beneficial ownership of common shares increased to 994,885.
Concurrently, Mr. Thye also acquired 150,944 warrants, each priced at $0.125, with an exercise price of $1.2.
These warrants became exercisable on the transaction date, June 18, 2025, and are set to expire on June 18, 2030, with each warrant underlying one common share.

Sentiment

Score: 8

Explanation: The acquisition of a significant number of shares and warrants by the CEO and CMO indicates strong insider confidence in the company's future prospects, which is a positive signal for investors.

Positives

The CEO and CMO, Dirk Thye, significantly increased his direct beneficial ownership in Quince Therapeutics, which typically signals strong insider confidence in the company's future performance and valuation.
The acquisition of both common shares and warrants demonstrates a substantial personal investment by a key executive, aligning management's interests with those of shareholders.

Future Outlook

Industry Context

Related Party Transactions

Acquisition of 150,944 common shares and 150,944 warrants by Dirk Thye, CEO and CMO of Quince Therapeutics, Inc., from the issuer.

Stakeholder Impact

Shareholders: The significant increase in insider ownership by a key executive may be perceived as a strong vote of confidence, potentially leading to increased investor interest and positive sentiment towards the stock.
Employees: No direct impact on employees is indicated by this transaction.
Customers: No direct impact on customers is indicated by this transaction.
Suppliers: No direct impact on suppliers is indicated by this transaction.
Creditors: No direct impact on creditors is indicated by this transaction.

Key Dates

Date	Description
06/18/2025	Date of earliest transaction for the acquisition of common shares and warrants.
06/18/2025	Date warrants became exercisable.
06/20/2025	Signature date of the reporting person, Dirk Thye.
06/18/2030	Expiration date of the acquired warrants.

Recommendation

buy

Keywords

Quince Therapeutics, QNCX, Dirk Thye, insider trading, Form 4, share acquisition, warrants, beneficial ownership, CEO, CMO

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.